The effects of setarud on the immunological status of HIV-positive patients: Efficacy of a novel multi-herbal drug

سال انتشار: 1396
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 386

فایل این مقاله در 10 صفحه با فرمت PDF قابل دریافت می باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_AJP-7-3_005

تاریخ نمایه سازی: 18 تیر 1398

چکیده مقاله:

Objective: This study examines the effect of the addition of IMOD, a novel multi-herbal drug to the highly active anti-retroviral therapy (HAART) regimen, on the immunological status of HIV-positive patients. Materials and Methods: A randomized two-parallel-group (HAART group versus HAART+IMOD group), pretest-posttest design was used.Sixty patients with indications for treatment with the HAART regimen participated. One week before and 2 days after the treatments, immunological parameters including total lymphocyte count (TLC) and CD4 cell count were assessed.The intervention group received the HAART regimen plus IMOD every day for 3 months. The control group received only the HAART regimen every day for 3 months. Results: In the intervention group, a significant difference was observed in CD4between before and after drug therapy (CD4 was increased). However, in the control group, the difference in CD4 was not significant before and after drug therapy. The difference in TLC was not significantly different between the two groups before and after therapy. Nevertheless, TLC was higher in the intervention group. Conclusion: IMOD (as a herbal drug) has been successfully added to the HAART regimen to improve the immunological status of HIV-positive patients.

نویسندگان

Mehdi Gholamzadeh Baeis

Young Researchers and Elites Club, Qom Branch, Islamic Azad University, Qom, I. R. Iran

Ghasem Amiri

Infectious disease specialist, Qom University of Medical Sciences, Qom, I. R. Iran.

Mojtaba Miladinia

Nursing Care Research Center in Chronic Diseases, School of Nursing and Midwifery, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, I. R. Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Panel on Antiretroviral Guidelines for Adults and Adolescents. 2008. Guidelines ...
  • Azonov J, Khorram Khorshid H, Novitsky Y, Farhadi M, Ghorbanoghli ...
  • Bangsberg DR, Moss AR, Deeks SG .2004. Paradoxes of adherence ...
  • Barbaro G, Barbarini G .2011. Human immunodeficiency virus & cardiovascular ...
  • Burgoyne RW, Tan DHS .2008. Prolongation and quality of life ...
  • Cerqueira DM, Amorim RM, Silva RR, Camara GN, Brígido MM, ...
  • Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. ...
  • Egger M, May M, Chêne G. 2002. Prognosis of HIV-1-infected ...
  • Fellay J, Ledergerber B, Ledergerber B, Bernasconi E, Furrer H, ...
  • Gengis EH, Deeks SG .2009. CD4+ T Cell Recovery with ...
  • Gertsch J, Viveros-Paredes JM, Taylor P .2011. Plant immunostimulants—Scientific paradigm ...
  • Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson ...
  • Ho DD. 1995. Time to Hit HIV, Early and Hard. ...
  • Khairandish P, Mohraz, M, Farzamfar B, Abdollahi M, Shahhosseiny M.H, ...
  • Khorram Khorshid HR, Novitsky YA, Abdollahi M .2008. Studies on ...
  • Khorshid H, Azonov J, Novitsky Y, Farzamfar B, Shahhosseiny M. ...
  • Lederman MM. 2001. Immune restoration and CD4+ T-cell function with ...
  • Li TS, Tubiana R, Katlama C, Calvez V, Mohand HA, ...
  • Lucas GM .2005. Antiretroviral adherence, drug resistance, viral fitness and ...
  • Lutwama F, Serwadda R, Mayanja-Kizza H, Shihab HM, Ronald A, ...
  • MacLennan CA, Liu MK, White SA, van Oosterhout JJ, Simukonda ...
  • Malta M, Strathdee SA, Magnanini MMF, Bastos FI. 2008. Adherence ...
  • May MT, Ingle SM .2011. Life expectancy of HIV-positive adults: ...
  • Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, ...
  • Mohraz M, Khairandish P, Kazerooni PA, Davarpanah M.A, Shahhosseiny M. ...
  • Mohraz M, Sedaghat A, SeyedAlinaghi Sasheri H, Mohammaddoust S, Gharibdoost ...
  • Montessori V, Press N, Harris M, Akagi L, Montaner JSG ...
  • Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT. ...
  • Mwamburi D, Ghosh M, Fauntleroy J, Gorbach S, Wanke C. ...
  • Nachega J, Marconi V, van Zyl G, Gardner E, Preiser ...
  • Nachega JB, Mills EJ, Schechter M. 2010. Antiretroviral therapy adherence ...
  • Orrell C .2005. Antiretroviral adherence in a resource-poor setting. Curr ...
  • Orsi F, d Almeida C .2010. Soaring antiretroviral prices, TRIPS ...
  • Paydary K, Emamzadeh-Fard S, Khorram Khorshid H, Kamali K, SeyedAlinaghi ...
  • Roca B, Gómez CJ, Arnedo A .1999. Stavudine, lamivudine and ...
  • Sax PE, Baden LR .2009. When to Start Antiretroviral Therapy ...
  • Schreibman T, Friedland G .2004. Use of Total Lymphocyte Count ...
  • Schwartländer B, Stover J, Walker N, Bollinger L, Gutierrez JP, ...
  • SeyedAlinaghi S, Paydary K, Emamzadeh-Fard S, Mohraz M .2012. Treatment ...
  • Siegfried N, Uthman O, Rutherford G .2010. Optimal time for ...
  • Spencer RC .2000. Mandell, Douglas and Bennett s Principles and ...
  • Vogel M, Schwarze-Zander C, Wasmuth J-C, Spengler U, Sauerbruch T, ...
  • Zabihollahi R, Namazi R, Aghasadeghi MR, Esfahani AF, Sadat SM, ...
  • نمایش کامل مراجع